Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 13/20 | 0.64 |
| ▸ | PARP11 | Q9NR21 | 10/20 | 0.64 |
| ▸ | PARP1 | P09874 | 5/20 | 0.56 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.56 |
| ▸ | GRM5 | P41594 | 5/20 | 0.54 |
| ▸ | F7 | P08709 | 1/20 | 0.50 |
| ▸ | F3 | P13726 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10286762 | 0.81 | CA12 (0.53) | PARP10PARP11PARP1GRM5 | |
| SCHEMBL1417646 | 0.78 | PARP10 (0.64) | PARP10PARP11PARP1PDPK1GRM5 | |
| SCHEMBL29978302 | 0.78 | PARP10 (1.00) | PARP10PARP11PARP1PDPK1GRM5 | |
| SCHEMBL279903 | 0.78 | PARP10 (1.00) | PARP10PARP11PARP1PDPK1GRM5 | |
| SCHEMBL1315035 | 0.78 | PARP10 (0.74) | PARP10PARP11PARP1PDPK1GRM5 | |
| SCHEMBL1002712 | 0.78 | PARP10 (1.00) | PARP10PARP11PARP1PDPK1GRM5 | |
| SCHEMBL15727824 | 0.78 | PARP10 (0.64) | PARP10PARP11PARP1PDPK1GRM5 | |
| SCHEMBL3152603 | 0.78 | PARP10 (0.64) | PARP10PARP11PARP1PDPK1GRM5 | |
| SCHEMBL794160 | 0.78 | PARP10 (0.74) | PARP10PARP11PARP1PDPK1GRM5 | |
| SCHEMBL3946742 | 0.75 | PARP10 (0.60) | PARP10PARP11PARP1PDPK1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299077-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2012-10-30 | — | — | US | disclosed |
| US-20100222325-A1 | Inhibitors of Bruton's Tyrosine Kinase | BERTHEL STEVEN | 2010-09-02 | — | — | US | disclosed |
| US-7683064-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2010-03-23 | — | — | US | disclosed |
| US-7105509-B2 | Benzodiazepine derivatives as APP modulators | MERCK SHARP & DOHME LIMITED (GB) | 2006-09-12 | — | — | US | disclosed |
| WO-2006034480-A2 | SULFONAMIDE BICYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20040082572-A1 | Benzodiazepine derivatives as app modulators | MERCK SHARPE & DOHME LIMITED (GB) | 2004-04-29 | — | — | US | disclosed |
| EP-1294702-A1 | BENZODIAZEPINE DERIVATIVES AS APP MODULATORS | MERCK SHARP & DOHME LTD. (GB) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001090084-A1 | BENZODIAZEPINE DERIVATIVES AS APP MODULATORS | MERCK SHARP & DOHME LIMITED (GB) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082572-A1 | Benzodiazepine derivatives as app modulators | BACE1, PSEN1, APP | PARP10 2420/4885PARP11 1487/4885PARP1 3023/4885 |
| US-20100222325-A1 | Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LYN | PARP10 1163/4885PARP11 971/4885PARP1 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.